These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14986695)

  • 21. Additional insights into pergolide-associated valvular heart disease.
    Lanier WL
    Mayo Clin Proc; 2003 Jun; 78(6):684-6. PubMed ID: 12934776
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined pergolide-associated valvular heart disease and achilles tendon contractures.
    Freeman WD; Dorsher PT; Safford RE; Van Gerpen J; Edwards WD
    Acta Med Acad; 2012; 41(2):228-30. PubMed ID: 23331401
    [No Abstract]   [Full Text] [Related]  

  • 23. Pergolide-induced ergotism.
    Morgan JC; Sethi KD
    Neurology; 2006 Jul; 67(1):104. PubMed ID: 16832086
    [No Abstract]   [Full Text] [Related]  

  • 24. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Valvular heart disease associated with the treatment of Parkinson disease].
    Rasmussen VG; Dupont E; Østergaard K; Egeblad H
    Ugeskr Laeger; 2006 Jun; 168(26-32):2542-4. PubMed ID: 16824407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valvular heart disease in pergolide-treated Parkinson's disease.
    Scozzafava J; Takahashi J; Johnston W; Puttagunta L; Martin WR
    Can J Neurol Sci; 2006 Feb; 33(1):111-3. PubMed ID: 16583734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide.
    Chung EJ; Yoon WT; Kim JY; Lee WY
    Mov Disord; 2006 Apr; 21(4):586-7. PubMed ID: 16482572
    [No Abstract]   [Full Text] [Related]  

  • 28. Pergolide-induced retroperitoneal fibrosis.
    Mondal BK; Suri S
    Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pergolide-associated valvular heart disease.
    Waller EA; Kaplan J
    Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.
    Flowers CM; Racoosin JA; Lu SL; Beitz JG
    Mayo Clin Proc; 2003 Jun; 78(6):730-1. PubMed ID: 12934784
    [No Abstract]   [Full Text] [Related]  

  • 31. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P; Fahn S; Frucht SJ
    Mov Disord; 2004 Jun; 19(6):699-704. PubMed ID: 15197712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quetiapine in a case with Parkinson disease and pathological gambling.
    Sevincok L; Akoglu A; Akyol A
    J Clin Psychopharmacol; 2007 Feb; 27(1):107-8. PubMed ID: 17224732
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hypersexuality during use of levodopa].
    van Puijenbroek EP; Diemont WL
    Ned Tijdschr Geneeskd; 2003 May; 147(20):990. PubMed ID: 12784535
    [No Abstract]   [Full Text] [Related]  

  • 36. [Ergoline-induced retroperitoneal fibrosis].
    Christoffersen CL; Siboni AH; Boisen E; Ladefoged C; Rasmussen C; Christensen-Dalsgaard S; Jakobsen P; Rasmussen LD; Schlander S
    Ugeskr Laeger; 2006 Apr; 168(17):1667; author reply 1667. PubMed ID: 16674890
    [No Abstract]   [Full Text] [Related]  

  • 37. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.
    Oury C; Maréchal P; Donis N; Hulin A; Hego A; Tridetti J; Nguyen ML; Dulgheru R; Fillet M; Nchimi A; Lancellotti P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 40. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease.
    Kunkler RB; Osborn DE; Abbott RJ
    Br J Urol; 1998 Jul; 82(1):147. PubMed ID: 9698685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.